



RDPAC Factbook

中国外商投资企业协会药品 研制和开发工作委员会概况



中国外商投资企业协会药品研制和开发工作委员会
China Association of Enterprises with Foreign Investment
R&D-based Pharmaceutical Association Committee



关于中国外商投资企业协会 药品研制和开发工作委员会 About RDPAC

中国外商投资企业协会药品研制和开发工作委员会（外资协会药研委，RDPAC）系中国外商投资企业协会的分支机构，服务于具备研究开发能力的全球领先的跨国制药企业在华投资实体。

The R&D-Based Pharmaceutical Association Committee (RDPAC), representing the China operations of leading multinational pharmaceutical companies with R&D capabilities, is a committee within the China Association of Enterprises with Foreign Investment (CAEFI).

RDPAC致力于携手主要利益相关方开展国际合作，搭建政府和行业沟通的桥梁，倡导可持续的政策，激励医药创新，确保创新药尽早广泛地惠及中国患者。同时，支持建立和完善中国医药创新生态系统，促进医药行业实现高质量发展，助力“健康中国”建设，增进中国人民的健康和福祉。

Through collaboration with key stakeholders to promote international cooperation and bridge communications between the government and the industry, RDPAC advocates sustainable policies that incentivize pharmaceutical innovation to ensure novel medicines benefit Chinese patients as early and as extensively as possible. It is dedicated to elevating China's pharmaceutical innovation ecosystem to foster higher-quality industry development, and to contributing to 'Healthy China' to improve the health and well-being of people in China.



中国外商投资企业协会药品研制和开发工作委员会
China Association of Enterprises with Foreign Investment
R&D-based Pharmaceutical Association Committee



RDPAC成员创新底蕴深厚

RDPAC member companies boast a long history of innovation

RDPAC成员成立时间

Years in Operation for RDPAC Member Companies

 **04**

成员
Member
Companies

200年及以上历史

More than 200
years of operational
experience

100-200年历史

100-200 years
of operational
experience

 **11**

成员
Member
Companies

50-100年历史

50-100 years of
operational experience

50年历史以内

Less than 50 years
of operational
experience

 **26**

成员
Member
Companies

 **06**

成员
Member
Companies

RDPAC成员进入中国时间

Length of Time RDPAC Member Companies Have Operated in China

 **25**

成员
Member
Companies

30年或以上

30 years or more

20-30年

20-30 years

 **09**

成员
Member
Companies

10-20年

10-20 years

 **08**

成员
Member
Companies

10年以内

Within 10 years

 **05**

成员
Member
Companies

资料来源: RDPAC成员
Source: RDPAC members

RDPAC成员持续引入新药

RDPAC member companies consistently bring innovative drugs into China

1999年到2023年，RDPAC成员累计向中国市场引进了超过800种创新药物。

Between 1999 and 2023, RDPAC member companies cumulatively introduced over 800 innovative drugs into the Chinese market.

2023年度药品审评报告中 获批新药数量*

Approved new drugs
as per the 2023 Annual
Drug Review Report
(CDE)

75

本土企业及非RDPAC成
员获批新药数量

Approved new drugs
of Chinese companies
and non-RDPAC
member companies

51

RDPAC成员获
批新药数量

Approved new drugs
of RDPAC member
companies

60%

40%

RDPAC成员获批新药数量* 按药品类型分 (2023)

Approved new drugs of
RDPAC member companies
by drug registration
categories (2023)

3

个1类新药
Category 1
new drugs

18

个3.1类生物药
Category 3.1
biological
drugs

30

个5.1类化药
Category 5.1
chemical drugs

2%

14%

24%

注释：新药包含1类、5.1类化学药品，1类、3.1类生物制品

Note: New drugs include Category 1 / 5.1 chemical drugs and Category 1 / 3.1 biological drugs

资料来源：《2023年度药品审评报告》

Source: 2023 Annual Drug Review Report (CDE)

RDPAC成员秉持“扎根中国，服务中国”

RDPAC member companies committed to In China for China

2023年RDPAC成员公司对中国经济的贡献

RDPAC member companies' contribution to the Chinese economy (2023)



纳税总计

超**300**亿元

Tax contribution
> RMB 30bn



20家成员企业投资总额

超**370**亿元

Total investment
> RMB 37bn for the
20 reported RDPAC
member companies



14家成员企业研发投入

超**80**亿元

R&D expenditures
> RMB 8bn for the 14
reported RDPAC member
companies

提升诊疗服务水平和质量

Improve the capacity and quality of
healthcare service

提升本土创新能力和质量

Enhance the capabilities and quality of
local innovation

开展国际合作研发 加速新药研发进程

Engage in international collaboration in
R&D to expedite new drug development

助力本土医药企业和创新 国际化，开拓海外市场

Support the integration of Chinese
pharmaceutical companies and
innovation into international
markets and pursue opportunities
in overseas markets

普及健康知识 提升公众健康意识

Disseminate health knowledge to
enhance public health awareness

建立行业投资基金 助力产业创新发展

Launch industry investment funds to drive
the industry's innovative growth

分享国际经验 孵化本土医药创新企业

Share international experience and
incubate Chinese pharmaceutical
innovation companies

共建中国医药数字化生态 提升产业效率和质量发展

Jointly develop the digital ecosystem
for China's pharmaceutical industry to
enhance industry efficiency and drive
high-quality development

构建可持续的中国生物医药创新生态

Establish a sustainable biopharmaceutical innovation
ecosystem in China




资料来源：RDPAC及其成员公司
Source: RDPAC and its member companies

RDPAC成员参与医药产业集群发展

RDPAC member companies play an active role in the development of pharmaceutical industry clusters

RDPAC成员设在中国的生产基地及研发中心(截至2023年底)

RDPAC Member Companies' Manufacturing Facilities and R&D Centers in China (By December 2023)



资料来源: RDPAC及其成员公司
Source: RDPAC and its member companies



北京市朝阳区东三环北路8号亮马河大厦1座506

Rm 506, Office Bldg 1, Landmark Tower, No.8 North
Dongsanhuan Rd. Chaoyang District, Beijing

电话Tel: +86 (10) 6590 7696

传真Fax: +86 (10) 6590 7697

邮箱E-mail: info@rdpac.org

www.rdpac.org

© 2025 RDPAC. All rights reserved.



中国外商投资企业协会药品研制和开发工作委员会
China Association of Enterprises with Foreign Investment
R&D-based Pharmaceutical Association Committee

